The decision about which biologic to choose for patients with Crohn’s disease used to be based largely on their preference for subcut or IV administration. And given the biologics and their biosimilars have similar rates of clinical remission, safety has become one of the main discriminators between therapies for many patients. Speaking to the limbic ...
Professor Rupert Leong: patient preference should guide biologic choice
By Mardi Chapman
20 Sep 2018